The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a more substantial reduction in body mass and benefit metabolic markers, particul